TABLE 1.

Baseline characteristics of randomized-controlled trials on short dual antiplatelet therapy following clopidogrel monotherapy.

Study	n	Ischemic and bleeding risk	Ethnicity	Clinical setting (%)		DAPT duration	Follow-up (months)	Primary endpoint	Primary endpoint met
				ACS	CCS
SMART-CHOICE	2,993	Low-to-moderate bleeding risk, low-to-moderate ischemic risk	East Asian	58	42	3 vs. 12 months	12	All-cause death, MI, or stroke	Yes
STOPDAPT-2	3,045	Low-to-moderate bleeding risk, low-to-moderate ischemic risk	East Asian	38	62	1 vs. 12 months	12	CV death, MI, ST, stroke, or TIMI major or minor bleeding	Yes
STOPDAPT-2-ACS	4,169	Low-to-moderate bleeding risk, mixed ischemic risk*	East Asian	100	0	1 vs. 12 months	12	CV death, MI, ST, stroke, or TIMI major or minor bleeding	NO
MASTER-DAPT	4,434	HBR, mixed ischemic risk*	Caucasian	49	51	1 vs. ≥3 months	11	All-cause death, MI, stroke, or BARC type 3, or 5	Yes

n, number of patients; ACS, acute coronary syndrome; CCS, chronic coronary syndrome; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; MI, myocardial infarction; CV, cardiovascular; ST, stent thrombosis; TIMI, Thrombolysis in Myocardial Infarction; BARC, Bleeding Academic Research Consortium. *Mixed ischemic risk includes low, moderate and high ischemic risk.